SGLT-2 inhibitors were examined in 10 studies [15,16,18,19,20,21,25,27,29,30], whereas the effects of GLP-1 agonists on MAGE, MBG levels, and percentage of time maintaining euglycemia among patients with diabetes were evaluated in six studies [17,22,23,24,26,28]. This evidence concerns the gene SLC5A2 and diabetes mellitus.